Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9225141 | 0.85 | MEN1 (0.69) | MAOBALOX5MAPTHPGDMEN1 | |
| SCHEMBL9225136 | 0.85 | MEN1 (0.69) | MAOBALOX5MAPTHPGDMEN1 | |
| SCHEMBL5376581 | 0.83 | BLM (0.50) | MAPTMEN1LMNAADRB2ADRB1 | |
| SCHEMBL5384385 | 0.81 | MAOB (0.55) | MAOBALOX5MAPTHPGDMEN1 | |
| SCHEMBL2313483 | 0.80 | MAPT (0.64) | MAPTMEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL8405878 | 0.80 | NPC1 (0.46) | MAPTHPGDMEN1LMNAKMT2A | |
| SCHEMBL5376930 | 0.79 | MAOB (0.48) | MAOBALOX5MAPTHPGDMEN1 | |
| SCHEMBL21543853 | 0.79 | TDP1 (0.55) | MAPTMEN1LMNAKMT2AKDM4E | |
| SCHEMBL3901893 | 0.78 | ALOX5 (0.58) | MAOBALOX5MAPTHPGDMEN1 | |
| SCHEMBL4653544 | 0.78 | MAOB (0.64) | MAOBMAOAMAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1436267-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033480-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | MAOB 2145/4885MAOA 2682/4885ALOX5 3527/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | MAOB 2860/4885MAOA 3671/4885ALOX5 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.